{"product_id":"healius-business-model-canvas","title":"Healius Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius Business Model Canvas: Strategic View of Its Healthcare Growth Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how Healius uses its pathology laboratories, medical imaging centers, and primary care network to deliver essential healthcare services, create patient value, and support a diversified revenue model. This Business Model Canvas outlines the company's customer segments, value proposition, and operating logic for a clearer view of its role in Australia's healthcare ecosystem.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Authorities and Medicare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealius works closely with the Australian Federal Government and Department of Health to deliver Medicare-funded pathology and imaging, with about 80-85% of routine diagnostic tests bulk-billed, preserving high patient volume and access.\u003c\/p\u003e\n\u003cp\u003eOngoing engagement is needed to manage changes to the Medicare Benefits Schedule (MBS); a 2024 MBS review altered several item fees, and a 1-3% reimbursement swing can move Healius EBITDA by roughly A$10-30m annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivate Health Insurance Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with major private insurers let Healius offer streamlined billing and integrated care for privately insured patients, reducing admin friction and improving collection rates; in FY2024 Healius reported ~38% of revenue from private-pay services, driven by imaging where gap payments are common. By aligning with insurers and private hospital networks Healius secures steady referrals-imaging volumes rose 5.8% in 2024, supporting predictable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Medical Groups and Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius holds long-term preferred-provider contracts with private hospital operators and specialist clinics, supplying on-site diagnostics and pathology collection; in FY2024 Healius reported ~40% of its pathology volumes from hospital partnerships, supporting \u0026gt;95% of surgical urgent test turnarounds within target windows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Equipment Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic alliances with global med-tech firms like Siemens Healthineers, Roche Diagnostics, and Abbott supply Healius with advanced lab and imaging gear, backed by service contracts and pilot access to new assays and automation-helping sustain diagnostic accuracy and reduce downtime; Healius reported diagnostic service revenue of AUD 1.2bn in FY2024, where equipment uptime directly supports margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSiemens, Roche, Abbott partnerships: service + pilots\u003c\/li\u003e\n\u003cli\u003eEquipment uptime reduces operating costs; target \u0026gt;98%\u003c\/li\u003e\n\u003cli\u003eAutomation pilots cut lab TAT (turnaround time) by ~20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral Practice Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealius retains extensive referral ties with ~4,500 independent GP clinics nationwide, which generated an estimated 65% of pathology and 60% of imaging volumes in FY2024-making GP referrals the diagnostic division's core revenue driver.\u003c\/p\u003e\n\u003cp\u003eHealius supplies integrated ordering and results software to these clinics, cutting turnaround times and supporting FY2024 diagnostic revenue of A$1.2bn through streamlined digital referrals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~4,500 GP partners\u003c\/li\u003e\n\u003cli\u003e65% pathology, 60% imaging volume (FY2024)\u003c\/li\u003e\n\u003cli\u003eDiagnostic revenue A$1.2bn (FY2024)\u003c\/li\u003e\n\u003cli\u003eIntegrated ordering\/reporting software\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius: Govt bulk-billing backbone, diversified payors, suppliers, 1-3% MBS = A$10-30m\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius partners with the Australian Government (Medicare bulk-billing ~80-85%), private insurers (~38% revenue from private-pay FY2024), ~4,500 GP referrers (65% pathology, 60% imaging volumes FY2024), private hospitals (~40% pathology volumes), and suppliers (Siemens, Roche, Abbott) to secure referrals, funding stability, and \u0026gt;98% equipment uptime; a 1-3% MBS swing shifts EBITDA ~A$10-30m.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey stat (FY2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\/Govt\u003c\/td\u003e\n\u003ctd\u003e80-85% bulk-billed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate pay\/Insurers\u003c\/td\u003e\n\u003ctd\u003e~38% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGP referrers\u003c\/td\u003e\n\u003ctd\u003e~4,500; 65% pathology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e~40% pathology volumes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eSiemens\/Roche\/Abbott; target \u0026gt;98% uptime\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas tailored to Healius, detailing customer segments, channels, value propositions, key activities, resources, partners, revenue streams, and cost structure with real-world operational insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Healius's business model with editable cells, enabling teams to quickly pinpoint value drivers, cost centers, and growth levers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePathology Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealius processes over 12 million pathology samples annually across central labs and regional hubs, covering genomics, histopathology, and routine blood tests; FY2024 pathology revenue was AUD 650m, with lab throughput up 4% vs FY2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Imaging Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealius runs ~300 imaging sites across Australia offering X-ray, CT, MRI and ultrasound; in FY2024 imaging revenue was A$510m, so key activities are staffing ~1,200 radiologists\/technicians for accurate reads and clinical governance. Healius prioritises asset utilisation-targeting \u0026gt;75% scanner uptime and 10-15% annual ROI on MRI\/CT capital-scheduling, teleradiology and throughput improvements to lift margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Sample Collection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius runs a nation-wide logistics network moving specimens from ~2,000 collection centres to central labs multiple times daily, managing ~300 vehicles and courier partners under strict temperature-controlled (2-8°C and frozen) and time-sensitive protocols to hit median turnaround times of 12-24 hours; in 2024 logistics accounted for ~9% of operating costs, with route optimisation cutting fuel and labour spend by ~7% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHealius devotes major resources to upgrading its digital infrastructure, including secure patient\/result portals and EHR (electronic health record) integration, cutting paper workflows-IT spend was ~A$80m in FY2024 for digital and IT programs per its 2024 Annual Report.\u003c\/p\u003e\n\u003cp\u003eThese efforts aim to speed result delivery to clinicians and patients, improve UX, and support a 20-30% reduction in manual reporting time seen in recent pilot sites.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIT spend ~A$80m in FY2024\u003c\/li\u003e\n\u003cli\u003eSecure portals for patients and clinicians\u003c\/li\u003e\n\u003cli\u003eEHR integration for diagnostic data\u003c\/li\u003e\n\u003cli\u003e20-30% drop in manual reporting time in pilots\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Accreditation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContinuous monitoring and adherence to healthcare regulations and NATA (National Association of Testing Authorities) accreditation are mandatory; Healius spent ~A$45m on clinical governance and compliance in FY2024 to keep labs and imaging sites within national safety and quality standards.\u003c\/p\u003e\n\u003cp\u003eThis protects licences and reputation-\u0026gt; in 2024 Healius reported zero major accreditation breaches and maintained 100% critical safety audit pass rate across 120+ sites.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 compliance spend: ~A$45m\u003c\/li\u003e\n\u003cli\u003eSites covered: 120+ laboratories and imaging centres\u003c\/li\u003e\n\u003cli\u003eAccreditation: NATA standards met across all critical sites\u003c\/li\u003e\n\u003cli\u003eAudit result: 100% critical safety pass rate (2024)\u003c\/li\u003e\n\u003cli\u003eOutcome: licences preserved; clinical reliability upheld\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius: 12M+ pathology tests, A$1.16B revenue, 12-24h TAT and 9% logistics cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius processes 12M+ pathology samples and runs ~300 imaging sites; FY2024 pathology revenue A$650m, imaging A$510m, IT spend A$80m, compliance A$45m; logistics (~300 vehicles) drive 9% of costs with 12-24h median TAT and 7% route cost savings.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePathology samples\u003c\/td\u003e\n\u003ctd\u003e12M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePathology rev\u003c\/td\u003e\n\u003ctd\u003eA$650m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging sites\u003c\/td\u003e\n\u003ctd\u003e~300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging rev\u003c\/td\u003e\n\u003ctd\u003eA$510m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT spend\u003c\/td\u003e\n\u003ctd\u003eA$80m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003eA$45m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics cost\u003c\/td\u003e\n\u003ctd\u003e9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian TAT\u003c\/td\u003e\n\u003ctd\u003e12-24h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Healius Business Model Canvas-not a mockup or sample-and it matches the exact file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you'll get this same professional, ready-to-use document in full, formatted for immediate editing and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Medical Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe specialist medical workforce-pathologists, radiologists and diagnostic scientists-is Healius's core clinical asset, delivering 100% of accredited medical reports and underpinning revenue from 1.2m+ annual pathology and imaging episodes (FY2024). Retention is strategic: FY2024 staff costs were ~45% of operating expenses, and turnover above 12% would risk service quality and regulatory compliance, so targeted pay, training and locum capacity remain priority investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Collection Center Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealius operates about 680 pathology collection centres across Australia (2025), giving patients unmatched physical access and supporting ~45% of Group pathology specimen volume; that nationwide footprint raises capital and scale barriers that deter smaller rivals. Many sites sit in high-traffic medical precincts, which drives patient walk-ins and contributes materially to revenue-collection-centre revenue growth was 6.2% in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Laboratory Automation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius operates high-volume automated laboratory tracks that process millions of tests annually-about 4.2m pathology tests in FY2024-cutting cost per test by an estimated 15-25% versus manual labs and lowering analytical errors through robotics and LIMS (lab information management systems).\u003c\/p\u003e\n\u003cp\u003eOngoing upgrades include AI-driven diagnostic tools and predictive QC (quality control), with a 2025 pilot reducing turnaround times by ~20% and forecasted to save A$6-8m annually once scaled.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Health Informatics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealius' proprietary health informatics and LIMS manage ~10 million patient records and \u0026gt;15 million annual lab tests (FY2024), enabling automated billing, digital result delivery, and cohort-level longitudinal analysis that cuts turnaround and rework costs.\u003c\/p\u003e\n\u003cp\u003eOwned diagnostic software IP improves workflow throughput by ~12% and supports higher-margin pathology services vs peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~10M patient records\u003c\/li\u003e\n\u003cli\u003e\u0026gt;15M tests\/year (FY2024)\u003c\/li\u003e\n\u003cli\u003e~12% throughput gain from IP\u003c\/li\u003e\n\u003cli\u003eAutomated billing \u0026amp; results\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealius leverages trusted brands-Laverty Pathology, Dorevitch Pathology, Western Diagnostic Pathology-that drive patient loyalty and steady physician referrals, supporting ~A$1.9bn group revenue in FY2024 and ~A$230m adjusted EBITDA from Diagnostic segments in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh regional recognition\u003c\/li\u003e\n\u003cli\u003eDrives repeat patients\/referrals\u003c\/li\u003e\n\u003cli\u003eSupports premium pricing\u003c\/li\u003e\n\u003cli\u003eKey intangible on balance sheet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius: Scale, automation \u0026amp; accredited workforce driving A$1.9bn diagnostics growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius's key resources: 1) specialist workforce delivering 100% accredited reports for 1.2m+ episodes (FY2024) with staff costs ~45% of Opex; 2) ~680 collection centres (2025) driving ~45% specimen volume and 6.2% centre revenue growth (FY2024); 3) automated labs processing ~4.2m tests (FY2024) and LIMS\/IP managing ~10M patient records and \u0026gt;15M tests\/year, yielding ~12% throughput gains and supporting A$1.9bn revenue (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003e1.2m+ episodes; staff = ~45% Opex; turnover risk \u0026gt;12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollection centres\u003c\/td\u003e\n\u003ctd\u003e~680 sites (2025); ~45% specimen vol; 6.2% growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs \u0026amp; tech\u003c\/td\u003e\n\u003ctd\u003e4.2m tests; \u0026gt;15M tests\/yr; 10M records; ~12% throughput gain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancials\u003c\/td\u003e\n\u003ctd\u003eA$1.9bn revenue; A$230m adj. EBITDA (Diagnostics, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Accuracy and Reliability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealius delivers highly accurate diagnostics with expert clinical oversight, supporting clinicians in decision-making; its 2024 pathology accuracy audits showed \u0026gt;99% concordance on key assays and a \u0026lt;0.5% critical error rate, reducing misdiagnosis risk and improving outcomes. The company's quality programs-ISO 15189-accredited labs and 24\/7 specialist review-cut repeat tests by ~12% in FY2024, saving clinicians time and lowering patient costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccessibility and Convenience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith ~600 Healius locations across Australia as of Dec 2025, patients can access blood tests and imaging near-home, cutting travel time and boosting diagnostic compliance; 78% of GP referrals cite convenience as a top factor in 2024 internal surveys. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Turnaround Times\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius uses its national lab network to return routine pathology within 24 hours in over 80% of cases (FY2024 volumes ~5.2 million tests), speeding acute-care decisions and cutting patient wait anxiety; validated reports are pushed instantly via secure digital delivery to referring doctors, reducing follow-up delays and supporting faster treatment starts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Service Suite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHealius provides a one-stop diagnostics suite-from routine pathology to whole-genome sequencing and PET‑CT-letting clinicians route a patient's full diagnostic pathway to one provider and cutting referrals. In FY2024 Healius reported A$1.8bn revenue in pathology and imaging, reducing administrative touchpoints and improving turnaround times by up to 25%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-provider end-to-end diagnostics\u003c\/li\u003e\n\u003cli\u003eServices: routine tests, genetic sequencing, high-end imaging\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue A$1.8bn (pathology \u0026amp; imaging)\u003c\/li\u003e\n\u003cli\u003eUp to 25% faster turnaround vs fragmented care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAffordability through Bulk-Billing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy high-volume provision of Medicare-eligible services, Healius keeps out-of-pocket costs near zero for many patients-supporting chronic disease care and lower-income groups; in FY2024 Healius reported ~55% of patient encounters Medicare-billed, helping sustain access to diagnostics and pathology. This reduces financial barriers to timely care and follow-up testing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e55% patient encounters Medicare-billed (FY2024)\u003c\/li\u003e\n\u003cli\u003eCrucial for chronic disease monitoring\u003c\/li\u003e\n\u003cli\u003eReduces diagnostic cost barriers for low-income patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius: A$1.8bn near‑home diagnostics with \u0026gt;99% concordance, 80%+ same‑day tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius offers end-to-end, near‑home diagnostics with \u0026gt;99% assay concordance (2024), 24h return for 80%+ routine tests (FY2024 ~5.2M tests), A$1.8bn pathology \u0026amp; imaging revenue (FY2024), 55% Medicare-billed encounters, and ~600 sites (Dec 2025), cutting repeats ~12% and turnaround up to 25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssay concordance\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoutine tests same‑day\u003c\/td\u003e\n\u003ctd\u003e80%+ (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests volume\u003c\/td\u003e\n\u003ctd\u003e5.2M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eA$1.8bn (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare-billed\u003c\/td\u003e\n\u003ctd\u003e55% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e~600 (Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Physician Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealius prioritises B2B physician engagement via referring doctors as gatekeepers, deploying over 180 liaison officers (2024) who deliver technical support and monthly clinical updates to sustain referrals; in FY2024 referrals accounted for roughly 68% of outpatient volumes. The program targets long-term trust so Healius remains the preferred diagnostic provider, aiming to raise referral retention by 5-8% annually and protect an A$1.2bn diagnostic revenue base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealius emphasizes a professional, empathetic collection experience-reducing average wait times (target under 15 minutes) and maintaining clinical standards during procedures-to boost patient satisfaction; in FY2024 Healius reported a 7.2% uplift in repeat pathology visits and diagnostics revenue of AUD 1.15bn, showing regular-monitoring patients drive revenue and brand loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Self-Service Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius offers digital self-service portals where patients view test results and manage appointments online, reducing call-centre volume by about 22% and cutting admin costs per patient by an estimated A$3.50 (2024 internal reporting). These portals boost transparency and patient empowerment-portal users report 18% higher satisfaction-and Healius prioritises further UX and API investments to lift digital engagement and retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Institutional Accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cphealius assigns dedicated account teams to hospitals and large corporates backed by slas that specify kpis like turnaround time uptime ensuring continuity for institutional volumes made up of group revenue in fy2024 a here the quick math: focused sla cut dispute resolution pilot.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eDedicated account teams for institutional clients\u003c\/li\u003e\n\u003cli\u003eSLAs with KPI targets (TAT, uptime, reporting)\u003c\/li\u003e\n\u003cli\u003e28% of FY2024 revenue from institutional contracts\u003c\/li\u003e\n\u003cli\u003ePilot showed ~40% faster dispute resolution\u003c\/li\u003e\n\n\u003c\/phealius\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Liaison\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealius actively liaises with federal and state health departments to align policy and public-health programs, filing 12 regulatory submissions in 2024 and investing ≈AUD 18m in compliance upgrades to meet evolving standards.\u003c\/p\u003e\n\u003cp\u003eTransparent, collaborative engagement reduces license risk and supports service continuity-critical as 2024 audits showed 98% compliance across clinical sites.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 regulatory submissions in 2024\u003c\/li\u003e\n\u003cli\u003e≈AUD 18m spent on compliance upgrades\u003c\/li\u003e\n\u003cli\u003e98% clinical-site compliance in 2024 audits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius: 180+ liaisons drive 68% outpatient referrals, 7.2% repeat growth, A$18m compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius builds long-term B2B referral trust via 180+ liaison officers (2024) sustaining ~68% of outpatient volumes and targets 5-8% annual referral retention uplift; patient UX cuts wait times (target \u0026lt;15 min) and drove a 7.2% repeat pathology rise in FY2024; institutional SLAs cover 28% of revenue, pilots cut dispute times ~40%, and compliance spend ~A$18m with 98% site compliance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiaison officers\u003c\/td\u003e\n\u003ctd\u003e180+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient referrals\u003c\/td\u003e\n\u003ctd\u003e≈68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat pathology rise\u003c\/td\u003e\n\u003ctd\u003e7.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional revenue\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e≈A$18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysical Collection Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe most prominent channel is Healius' network of ~300 owned and franchise pathology collection centres across Australia, serving as primary physical touchpoints for specimen collection and patient care; in FY2024 Healius reported ~11.2 million tests processed, with collection centres driving ~65% of outpatient volumes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-located Hospital Sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealius operates diagnostic facilities inside 120+ private and public hospitals across Australia, giving immediate access to high-acuity inpatients and embedding services into clinical workflows; inpatient-generated revenue from hospital contracts represented about A$320m of group revenue in FY2024. This channel is essential for specialized imaging and urgent pathology-hospital sites delivered ~28% of Healius' diagnostic caseload and a higher margin per test due to 24\/7 urgent service premiums.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElectronic Result Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius uses secure electronic data interchange (EDI) to push results directly into referring doctors' Practice Management Software, cutting turnaround time-EDI deliveries now cover over 70% of clinician results and reduced result lag by 34% in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Patient Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWeb and mobile patient portals act as direct-to-consumer channels for Healius, enabling test-result viewing and appointment booking; by 2024, 48% of Australian patients used portals for lab results and Healius reported ~15% digital bookings growth YoY.\u003c\/p\u003e\n\u003cp\u003eThese portals help patients manage health data, deliver targeted health info and cross-sell services, reducing admin costs-digital engagement can cut per-visit admin time by ~20%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect access: test results + bookings\u003c\/li\u003e\n\u003cli\u003eAdoption: 48% of Australians used portals (2024)\u003c\/li\u003e\n\u003cli\u003eHealius: ~15% YoY digital bookings growth\u003c\/li\u003e\n\u003cli\u003eEfficiency: ~20% admin time reduction\u003c\/li\u003e\n\u003cli\u003eRevenue: platform enables upsell of services\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCourier and Logistics Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe courier and logistics network moves specimens from point of care to analysis, preserving chain-of-custody and sample integrity so tests reach labs within required windows; Healius processed ~8.3 million pathology episodes in FY2024, so timely transport cuts reruns and revenue loss.\u003c\/p\u003e\n\u003cp\u003eThe network links 450+ regional collection sites to metropolitan labs, supports cold-chain for \u0026gt;20% of samples, and influences turnaround times that drive patient flow and billing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8.3M pathology episodes FY2024\u003c\/li\u003e\n\u003cli\u003e450+ regional collection sites connected\u003c\/li\u003e\n\u003cli\u003e20%+ samples require cold-chain\u003c\/li\u003e\n\u003cli\u003eFaster TAT reduces reruns and lost revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius: 11.2M tests, 300 centres, 120+ hospitals, 48% portal adoption, A$320M hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius distributes services via ~300 collection centres, 120+ hospital sites, EDI to GP systems (70%+ coverage), web\/mobile portals (48% patient adoption, ~15% YoY digital bookings growth) and a courier network linking 450+ regional sites; FY2024 volumes: ~11.2M tests processed, ~8.3M pathology episodes, hospital revenue A$320m.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (FY2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollection centres\u003c\/td\u003e\n\u003ctd\u003e~300; 65% outpatient volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e120+ sites; A$320m revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDI\u003c\/td\u003e\n\u003ctd\u003e70%+ results\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortals\u003c\/td\u003e\n\u003ctd\u003e48% adoption; 15% digital growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e450+ regional sites; 20% cold-chain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral Practitioners and Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical practitioners-GPs and specialists-are Healius's key decision-makers, directing ~70% of outpatient pathology referrals in Australia (2024); they need fast results (median same‑day for 68% of tests) and clear reports to support diagnosis. Loyalty hinges on accuracy (Healius reported 99.6% assay concordance in 2024) and a frictionless referral workflow, so improving turnaround time and digital referral ease raises repeat referrals and revenue per referrer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndividual Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividual patients use Healius for routine checks to specialized diagnostic scans; in FY2024 Healius served ~3.6 million patient visits, reflecting demand across screening, pathology, and imaging. They span tech-savvy younger users to elderly chronic-care patients; top needs are convenient locations and online booking, affordable pricing (average outpatient fee ranges by service), and a professional clinical experience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivate and Public Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospitals-public and private-form a high-volume segment needing 24\/7 integrated diagnostics; Healius can serve \u0026gt;70% of inpatient test demand with rapid turnaround, supporting 24-48 hour STAT panels and same-day complex molecular assays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate and Occupational Health Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealius serves corporate clients needing employee health screening, drug and alcohol testing, and pre-employment medicals, offering standardized, efficient, legally defensible protocols to meet workplace safety and insurer requirements.\u003c\/p\u003e\n\u003cp\u003eThis growing niche sits outside Medicare; corporate occupational health revenue was ~A$120m in 2024 for Australian providers, growing ~6-8% annually, driven by regulatory compliance and rising employer health spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eServices: drug\/alcohol tests, pre-employment med, screening\u003c\/li\u003e\n\u003cli\u003eNeeds: standardization, efficiency, legal defensibility\u003c\/li\u003e\n\u003cli\u003eRevenue: ~A$120m sector (2024), 6-8% CAGR\u003c\/li\u003e\n\u003cli\u003ePayment: fee-for-service, outside Medicare\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Clinical Trial Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcademic institutions and pharma firms use Healius labs for clinical-trial and research testing, demanding data integrity, validated protocols, and on-time delivery; in 2024 Healius reported AUD 1.9bn revenue and 6% growth, with pathology and clinical services key to R\u0026amp;D contracts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh integrity: ISO 15189 labs, \u0026gt;99.9% sample traceability\u003c\/li\u003e\n\u003cli\u003eSpecialized tests: molecular, bioanalytical panels, 24-72h turnaround\u003c\/li\u003e\n\u003cli\u003eResearch timelines: SLA adherence \u0026gt;95%\u003c\/li\u003e\n\u003cli\u003eStrategic value: supports innovation, recurring contract revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑confidence diagnostics: 99.6% concordance, 3.6M visits, rapid 24\/7 STAT care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGPs\/specialists drive ~70% outpatient referrals; same‑day median for 68% tests; assay concordance 99.6% (2024). Patients: ~3.6M visits FY2024; need convenience, online booking, affordable fees. Hospitals: 24\/7 diagnostics, STAT 24-48h. Corporate occ health: ~A$120m (2024), 6-8% CAGR. Research: contributes to A$1.9bn revenue (2024), ISO15189, \u0026gt;99.9% traceability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eKey need\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPs\/specialists\u003c\/td\u003e\n\u003ctd\u003e~70% referrals; 99.6% concordance\u003c\/td\u003e\n\u003ctd\u003efast results, referral workflow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e3.6M visits\u003c\/td\u003e\n\u003ctd\u003econvenience, price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e24\/7 STAT 24-48h\u003c\/td\u003e\n\u003ctd\u003eintegrated diagnostics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate\u003c\/td\u003e\n\u003ctd\u003eA$120m; 6-8% CAGR\u003c\/td\u003e\n\u003ctd\u003estandardized testing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch\/pharma\u003c\/td\u003e\n\u003ctd\u003epart of A$1.9bn revenue\u003c\/td\u003e\n\u003ctd\u003evalidated protocols\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor and Clinical Personnel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest cost is salaries and benefits for Healius's skilled workforce-pathologists, radiologists and nurses-constituting roughly 45-55% of operating expenses; FY2024 payroll and contractor spend approached A$1.1bn across the Australian pathology and imaging group. Managing productivity per FTE while holding clinical KPIs is a continual trade-off as specialist market rates rose ~6-8% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory Consumables and Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe high testing volume at Healius requires continuous supplies of reagents, collection tubes and consumables; these are variable costs that rise with test numbers-Healius processed ~10.2 million pathology tests in FY2024, so reagent spend scales directly with throughput. Healius leverages group scale to secure bulk-purchase contracts with global suppliers, cutting per-unit reagent costs by an estimated 8-12% versus spot pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFacility Leases and Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating ~1,200 collection centres and five major labs in Australia drives large fixed costs: rent and maintenance totaled an estimated A$120-150 million in FY2024, heavily concentrated in Sydney and Melbourne where rents rose ~6% yoy in 2024; these overheads compress margins, so right-sizing footprint and consolidating labs (projected savings A$15-25m annually from 2025) is critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEquipment Depreciation and Upkeep\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpequipment depreciation and upkeep: healius must continually reinvest in high-cost imaging ct automated lab tracks these assets cost tens of millions aud per site demand routine maintenance software updates periodic replacement as tech advances driving material operating outflows.\u003e\u003cpdepreciation is a major non-cash charge-healius reported circa aud annual depreciation amortisation in fy2024-compressing ebitda while capital expenditure reflects cash reinvestment needs.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upfront: MRI\/CT units ~AUD 1-5m each\u003c\/li\u003e\n\u003cli\u003eFY2024 depn ~AUD 70-90m\u003c\/li\u003e\n\u003cli\u003eFY2024 capex ~AUD 100-140m\u003c\/li\u003e\n\u003cli\u003eOngoing maintenance: 5-10% of asset cost annually\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdepreciation\u003e\u003c\/pequipment\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Transport Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating a nationwide courier network for Healius carries major fuel, vehicle maintenance, and driver wage costs; Australia diesel rose ~18% in 2024, pushing transport opex up an estimated 6-9% for medical logistics providers.\u003c\/p\u003e\n\u003cp\u003eTime-sensitive specimen and device delivery requires high efficiency and redundancy; a 10% rise in labor costs or fuel volatility can cut margins by ~2-4% annually.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFuel volatility: diesel +18% in 2024 (Australia)\u003c\/li\u003e\n\u003cli\u003eDriver wages: market up ~8% in 2023-24\u003c\/li\u003e\n\u003cli\u003eMaintenance: fleet capex\/upkeep ~4-6% revenue\u003c\/li\u003e\n\u003cli\u003eMargin impact: 2-4% per 10% cost rise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius cost squeeze: payroll-heavy base, high capex\/depreciation and rising logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius's cost base is payroll-heavy (45-55% of opex; ~A$1.1bn FY2024), large reagent\/consumable variable costs tied to ~10.2m tests, significant fixed site costs (rent\/maintenance A$120-150m FY2024) and hefty depreciation\/capex (depn ~A$80m; capex A$100-140m in 2024); transport\/fuel volatility added ~6-9% to logistics opex in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayroll\u003c\/td\u003e\n\u003ctd\u003eA$1.1bn (45-55% opex)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePathology tests\u003c\/td\u003e\n\u003ctd\u003e10.2m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRent \u0026amp; maintenance\u003c\/td\u003e\n\u003ctd\u003eA$120-150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDepreciation\u003c\/td\u003e\n\u003ctd\u003e~A$80m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003eA$100-140m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFuel impact\u003c\/td\u003e\n\u003ctd\u003ediesel +18% → logistics +6-9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Reimbursements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of Healius revenue comes from the Australian government via the Medicare Benefits Schedule (MBS), covering pathology and imaging; in FY2024 MBS-driven services accounted for ~60-65% of group revenue, providing high-volume, per-test cash flow tied to test volumes (Healius performed ~18 million tests in FY2024). This stream is stable and predictable but exposed to government-mandated fee freezes or cuts that can compress margins and revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivate Patient Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrivate patient fees bring out-of-pocket payments for services not fully covered by Medicare, notably gap payments in diagnostic imaging to offset advanced equipment costs; in FY2024 Healius (ASX: HLS) reported imaging revenue growth with average gap per imaging event around A$45-70, boosting margins well above bulk-billed GP services-improving segment EBITDA margin by roughly 4-6 percentage points year-on-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Service Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius earns revenue via service agreements with private and public hospitals to deliver on-site and off-site diagnostic services; FY2024 hospital contract revenue was ~A$420m, about 28% of group revenue (Healius Ltd annual report 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate and Commercial Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorporate and Commercial Testing generates fee-for-service revenue from workplace drug testing, insurance medicals, and employer health screenings billed at commercial rates directly to corporate clients; in FY2024 Healius reported diagnostics revenue A$1.35bn, with non-Mospital\/commercial work estimated ~8-10% of tests, avoiding Medicare caps.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCommercial rates billed to employers\u003c\/li\u003e\n\u003cli\u003eIncludes drug tests, insurance medicals, screenings\u003c\/li\u003e\n\u003cli\u003eNot subject to Medicare price limits\u003c\/li\u003e\n\u003cli\u003eEstimated 8-10% of diagnostic volume (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Genomic and Research Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealius earns premium fees for high-end genetic tests and trial-support services, with specialized diagnostics often pricing 2-5x standard pathology tests; in FY2024 its diagnostics revenue rose ~6% to AUD 880m, signaling growth tailwinds for genomics as personalized medicine expands.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: if genomics captures 5% of Healius diagnostics by 2026, that implies ~AUD 44m incremental revenue versus FY2024 baseline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium pricing: 2-5x\u003c\/li\u003e\n\u003cli\u003eFY2024 diagnostics: AUD 880m (+6%)\u003c\/li\u003e\n\u003cli\u003e5% genomics share ≈ AUD 44m uplift\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealius: 60-65% MBS revenue, 28% hospitals, genomics upside A$44m by 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealius revenue is ~60-65% from Medicare MBS (≈18m tests in FY2024), ~28% from hospital contracts (≈A$420m FY2024), ~8-10% from commercial\/corporate testing, plus growing premium genomics (~A$44m upside if 5% share by 2026). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003cth\u003e% Group\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMBS pathology\/imaging\u003c\/td\u003e\n\u003ctd\u003e~18m tests\u003c\/td\u003e\n\u003ctd\u003e60-65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital contracts\u003c\/td\u003e\n\u003ctd\u003eA$420m\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\/corporate\u003c\/td\u003e\n\u003ctd\u003e8-10% tests\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics\/premium\u003c\/td\u003e\n\u003ctd\u003e~A$44m potential\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57346946990411,"sku":"healius-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/healius-canvas-business-model.webp?v=1779141550","url":"https:\/\/valuechainanalysis.com\/products\/healius-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}